28715-26-6

Basic information

• Product Name: 4,7-dimethylbenzofuran
• Synonyms: 4,7-dimethylbenzofuran
• CAS NO: 28715-26-6
• Molecular Formula: C₁₀H₁₀O
• Molecular Weight: 146.1858
• EINECS: 249-184-6
• Mol File: 28715-26-6.mol

Chemical Properties

• Boiling Point: 216°C (estimate)
• Flash Point: 86.4°C
• Appearance: /
• Density: 1.0410
• Vapor Pressure: 0.188mmHg at 25°C
• Refractive Index: 1.5490 (estimate)
• CAS DataBase Reference: 4,7-dimethylbenzofuran(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7-dimethylbenzofuran(28715-26-6)
• EPA Substance Registry System: 4,7-dimethylbenzofuran(28715-26-6)

Safety Data

• Hazardous Substances Data: 28715-26-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10O/c1-7-3-4-8(2)10-9(7)5-6-11-10/h3-6H,1-2H3

Upstream product

• 289891-92-5 2,2-diethyl-2,4-dimethylphenyl ether 
• 95-87-4 2,5-Dimethylphenol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 110-00-9 furan 
• 625-86-5 2,5-dimethylfuran 

Downstream Products

• 196520-11-3 methyl 4-[4-(4,7-dimethylbenzofuran-2-yl)-4-oxo-butanoyl]benzoate 
• 196520-04-4 methyl 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoate 

Relevant articles and documents

Characteristic flavor formation of thermally processed N-(1-deoxy-α-D-ribulos-1-yl)-glycine: Decisive role of additional amino acids and promotional effect of glyoxal

The role of amino acids and α-dicarbonyls in the flavor formation of Amadori rearrangement product (ARP) during thermal processing was investigated. Comparisons of the volatile compounds and their concentrations when N-(1-deoxy-α-D-ribulos-1-yl)-glycine r

Dioxazolones as masked ester surrogates in the Pd(ii)-catalyzed direct C-H arylation of 6,5-fused heterocycles

A simple and effective Pd(ii)-catalyzed regioselective C(2)-H arylation of 6,5-fused heterocycles with dioxazolones as a masked ester surrogate under mild conditions is reported. The significance of the arylation is highlighted by the new reactivity demonstrated in dioxazolones via proximal C-H activation of the cyclic carbonate of the hydroxamic acid functionality under protic conditions.

Direct Dimesitylborylation of Benzofuran Derivatives by an Iridium-Catalyzed C?H Activation with Silyldimesitylborane

Direct dimesitylborylation of benzofuran derivatives by a C?H activation catalyzed by an iridium(I)/N-heterocyclic carbene (NHC) complex in the presence of Ph2MeSi-BMes2 afforded the corresponding dimesitylborylation products in good to high yield with excellent regioselectivity. This method provides a straightforward route to donor–(π-spacer)–acceptor systems with intriguing solvatochromic luminescence properties.

Preparation method of benzofuran compound

The invention relates to a preparation method of a benzofuran compound. The preparation method comprises the following steps: putting a furan compound, acetic acid and a Lewis acid catalyst in a reaction vessel, reacting for 0.5-24 h at 80-160 DEG C, and separating and purifying to obtain the benzofuran compound. According to the preparation method provided by the invention, the furan compound isused as a reaction raw material, an acetic acid water solution is used as a solvent, Lewis acid is used as a catalyst, and at a mild reaction temperature (80-160 DEG C), the benzofuran compound is directly obtained through one-step reaction. The preparation method provided by the invention can synthesize the benzofuran compound with a corresponding structure and functional groups based on the structure and functional groups of the furan compound as a raw material, the raw material components are simple , and the process is convenient to operate; wherein the selectivity of the obtained benzofuran is as high as 99% in the process of synthesizing benzofuran by using furan, so that the method has industrial application prospects.

Retinoic acid agonists as preventive and therapeutic agents for nephritis

The present invention provides a therapeutic or prophylactic agent as a substitute for conventional steroids or immunosuppressive agents to treat or prevent systemic erythematosus, glomerulonephritis, lupus nephritis, idiopathic thrombocytopenic purpura or autoimmune anemia. The agent comprises a retinoic acid receptor agonist, specifically a retinoic acid receptor subtype α (RARα) agonist, including for example: (1) carboxylic acid compounds having condensed rings represented by the following formula: ?(wherein the rings L and M are condensed, are the same as or different from each other, and represent an aromatic hydrocarbon which may have a substituent group or a heterocycle which may have a substituent group; the rings A and B are independent of each other and represent an aromatic hydrocarbon ring or heterocycle which may have a substituent group; and D represents a carboxyl group which may have a protective group), (2) 4-{[(3,5-bistrimethylsilylphenyl)carbonyl]amino}benzoic acid, 4-{2-[5-(3-methoxymethyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl)pyrrolyl]}benzoic acid, etc.

Methods for preventing, inhibiting or treating graft rejection reactions in graft-versus-host disease (GVHD) and organ transplantation

The present invention provides remedies for graft-versus-host disease (GVHD) and graft rejection reactions in organ transplantation which comprise retinoic acid receptor (RAR) agonists as an active ingredient. Main examples thereof include 9-(4-methoxy-2,3,6-trimethylphenyl)-7,8-dimethylnona-2,4,6,8-tetraen-1-oic acid, 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalen-2-yl)propenyl]benzoic acid, 4-{2-[5-(4,7-dimethylbenzofuran-2-yl)pyrroyl]}benzoic acid, 4-{2-[5-(5-chloro-7-ethylbenzofuran-2-yl)pyrrolyl]}benzoic acid and 4-{2-[5-(4,7-dimethylbenzothiophen-2-yl)pyrrolyl]}benzoic acid.

Discovery of novel and potent retinoic acid receptor α agonists: Syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives

In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS- induced B-lymphocyte proliferation and exerted RARα selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.

Carboxylic acid derivatives having fused rings

The present invention provides a medicament exhibiting excellent retinoic acid receptor agonism. A Carboxylic acid derivative having a fused ring which is represented by the following formula or a pharmacologically acceptable salt thereof: {wherein the symbol represents a single bond or a double bond; X, Y, Z, P, Q, U, V and W are each a group represented by the formula: -O- or -S-, or a group represented by the formula: [wherein Rk (k: 1 to 8) is hydrogen, halogeno, optionally substituted lower alkyl or the like, with either of R7 and R8 being a group represented by the formula: (wherein A and B are each independently an optionally substituted aromatic hydrocarbon ring or an optionally substituted unsaturated heterocycle; and D is optionally protected carboxyl)]}.